- Details
- Description
Packaging Size:
30 film-coated tablets (1 × 30); HDPE container
Strength:
45 mg
Composition:
Dacomitinib INN 45 mg per film-coated tablet
Treatment:
Oral targeted anticancer medicine used as first-line treatment for certain patients with metastatic non-small-cell lung cancer (NSCLC) whose tumors have specific EGFR exon 19 deletion or exon 21 L858R mutations.
Form:
Film-coated tablet
Brand:
Daconib 45 mg
Quantity Unit:
Tablet
Manufacturer:
Everest Pharmaceuticals Ltd., Bangladesh
Daconib 45 mg is an oral targeted anticancer medicine manufactured by Everest Pharmaceuticals Ltd., Bangladesh. Each film-coated tablet contains Dacomitinib 45 mg, an irreversible tyrosine kinase inhibitor that targets the EGFR/HER family of signaling proteins. It is indicated as a first-line treatment for adults with metastatic non-small-cell lung cancer (NSCLC) whose tumors carry specific EGFR mutations, including exon 19 deletions or exon 21 L858R substitutions. Daconib is typically taken once daily and may be taken with or without food. Treatment should be prescribed and monitored by an oncology specialist.
Related Products
